Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MMP9 | P14780 | 3/20 | 0.51 |
| ▸ | MMP2 | P08253 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.39 |
| ▸ | GGH | Q92820 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27717200 | 1.00 | KMT2A (0.52) | KMT2AMMP9MMP2CA2CA1 | |
| SCHEMBL5495801 | 1.00 | KMT2A (0.52) | KMT2AMMP9MMP2CA2CA1 | |
| SCHEMBL4627986 | 0.87 | NAALAD2 (0.51) | MMP9NPSR1NAALAD2GGHGAA | |
| SCHEMBL4627982 | 0.87 | NAALAD2 (0.51) | MMP9NPSR1NAALAD2GGHGAA | |
| SCHEMBL13726857 | 0.87 | NAALAD2 (0.51) | MMP9NPSR1NAALAD2GGHGAA | |
| SCHEMBL2248455 | 0.85 | KMT2A (0.50) | KMT2AMMP9MMP2CA2CA1 | |
| SCHEMBL2021385 | 0.84 | ALDH1A1 (0.48) | KMT2AMMP9MMP2CA2CA1 | |
| SCHEMBL28694554 | 0.84 | ALDH1A1 (0.48) | KMT2AMMP9MMP2CA2CA1 | |
| SCHEMBL2021383 | 0.84 | ALDH1A1 (0.48) | KMT2AMMP9MMP2CA2CA1 | |
| SCHEMBL29908038 | 0.82 | NPSR1 (0.43) | KMT2AKIF11NPSR1NAALAD2GGH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101274958-A | Bioactive peptide, preparation thereof and application thereof | OCEAN UNIV CHINA (CN) | 2008-10-01 | — | — | CN | claimed |
| US-5618825-A | ENZYME INHIBITORS; ANTICOAGULANTS; VISION DISORDERS | PHARMACOPEIA, INC. (US) | 1997-04-08 | — | — | US | claimed |
| CN-120022382-A | Polyamino acid nanoparticle with lung targeting property, and preparation method and application thereof | 苏州大学 | 2025-05-23 | — | — | CN | disclosed |
| CN-113979886-B | Protective amino acid with side chain being amide and preparation method thereof | 成都市科隆化学品有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-116178520-B | Cationic peptide and application thereof | 浙江大学医学院附属第一医院 | 2024-04-19 | — | — | CN | disclosed |
| CN-111886020-B | Peptide macrocycles against acinetobacter baumannii | 豪夫迈·罗氏有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-116178520-A | Cationic peptide and application thereof | 浙江大学医学院附属第一医院 | 2023-05-30 | — | — | CN | disclosed |
| US-11628221-B2 | Peptide linker and combination for prodrugs activated by prostate-specific antigen | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-04-18 | — | — | US | disclosed |
| CN-108794422-B | Heterocyclic compounds as PD-L1 inhibitors | 南京圣和药业股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-113979886-A | Protected amino acid with amide side chain and preparation method thereof | 成都市科隆化学品有限公司 | 2022-01-28 | — | — | CN | disclosed |
| US-11129901-B2 | Peptide-linked ester prodrugs activated by prostate-specific antigen | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-09-28 | — | — | US | disclosed |
| WO-1998020350-A1 | COMBINATORIAL HYDROXY-AMINO ACID AMIDE LIBRARIES | PHARMACOPEIA, INC. (US) | 1998-05-14 | — | — | WO | disclosed |
| US-5734054-A | Hydroxy-amino acid amides | PHARMACOPEIA, INC. (US) | 1998-03-31 | — | — | US | disclosed |
| EP-0822200-A1 | Synthesis of analogs of PTH and PTrP | F. HOFFMANN-LA ROCHE AG (CH) | 1998-02-04 | — | — | EP | disclosed |
| WO-1997027315-A1 | COMBINATORIAL HYDROXYPROPYLAMINE LIBRARY | PHARMACOPEIA, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
| EP-0751765-A4 | SULFONAMIDE DERIVATIVES AND THEIR USE | PHARMACOPEIA INC (US) | 1997-05-28 | — | — | EP | disclosed |
| US-5618825-A | ENZYME INHIBITORS; ANTICOAGULANTS; VISION DISORDERS | PHARMACOPEIA, INC. (US) | 1997-04-08 | — | — | US | disclosed |
| EP-0751765-A1 | SULFONAMIDE DERIVATIVES AND THEIR USE | PHARMACOPEIA, INC. (US) | 1997-01-08 | — | — | EP | disclosed |
| WO-1995024186-A1 | SULFONAMIDE DERIVATIVES AND THEIR USE | PHARMACOPEIA, INC. (US) | 1995-09-14 | — | — | WO | disclosed |
| US-5230998-A | Viricides | AIDA DEVELOPMENT CORPORATION | 1993-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11628221-B2 | Peptide linker and combination for prodrugs activated by prostate-specific antigen | KLK3, DNPEP, FOLH1 | KMT2A 3018/4885MMP9 502/4885MMP2 196/4885 |
| US-11129901-B2 | Peptide-linked ester prodrugs activated by prostate-specific antigen | ACP3, KLK3, DNPEP | KMT2A 3205/4885MMP9 729/4885MMP2 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.